NICE’s decision not to approve Zytiga ‘frustrating’, says ICR
Zytiga is used for the treatment of newly diagnosed, advanced prostate cancer patients
Read Moreby Lucy Parsons | Jul 16, 2021 | News | 0
Zytiga is used for the treatment of newly diagnosed, advanced prostate cancer patients
Read Moreby Selina McKee | Jun 26, 2020 | News | 0
Around 4,000 men newly diagnosed with high-risk metastatic hormone-sensitive prostate cancer would have been eligible for treatment with the drug
Read Moreby Anna Smith | Jan 14, 2020 | News | 0
The group also accepted drugs for primary progressive multiple sclerosis and a rare form of lymphoma.
Read Moreby Selina McKee | Jun 6, 2018 | News | 0
It is looking unlikely that Janssen’s Zytiga plus androgen deprivation therapy and prednisone/prednisolone will become routinely available on the NHS as a first-line treatment for patients with high-risk hormone-sensitive metastatic prostate cancer.
Read Moreby Selina McKee | Nov 21, 2017 | News | 0
European regulators are allowing earlier use of Janssen’s Zytiga in the treatment pathway for metastatic prostate cancer.
Read Moreby Selina McKee | Oct 16, 2017 | News | 0
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended just one generic medicine for approval at its October meeting.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
